{"id":1877,"date":"2002-11-01T12:01:00","date_gmt":"2002-11-01T11:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/ein-neues-antikoagulanz-fondaparinux-natrium"},"modified":"2022-03-17T14:10:16","modified_gmt":"2022-03-17T13:10:16","slug":"ein-neues-antikoagulanz-fondaparinux-natrium","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/ein-neues-antikoagulanz-fondaparinux-natrium","title":{"rendered":"Ein neues Antikoagulanz: Fondaparinux-Natrium"},"content":{"rendered":"<p>Im M\u00e4rz 2002 hat die EMEA (Europ\u00e4ische Arzneimittelbeh\u00f6rde) europaweit ein neues, rein synthetisches Antikoagulanz zugelassen, Fondaparinux-Natrium (Arixtra von Sanofi Synthelabo). Informationen zur Substanz und zum Zulassungsverfahren sind auf der Homepage der EMEA nachzulesen (1). Wir haben \u00fcber eine Phase-II-Studie mit dieser Substanz bereits kurz berichtet (2). Fondaparinux-Natrium bindet wie Heparin an Antithrombin III (AT III) [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im M\u00e4rz 2002 hat die EMEA (Europ\u00e4ische Arzneimittelbeh\u00f6rde) europaweit ein neues, rein synthetisches Antikoagulanz zugelassen, Fondaparinux-Natrium (Arixtra von Sanofi Synthelabo). Informationen zur Substanz und zum Zulassungsverfahren sind auf der Homepage der EMEA nachzulesen (1). Wir haben \u00fcber eine Phase-II-Studie mit dieser Substanz bereits kurz berichtet (2). Fondaparinux-Natrium bindet wie Heparin an Antithrombin III (AT III) [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[61,3857,2457,4112,4113,4114,51,2066,55],"class_list":["post-1877","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-beinvenenthrombose","tag-ephesus-studie","tag-fondaparinux","tag-pentamaks-studie","tag-pentathlon-2000-studie","tag-penthifra-studie","tag-thrombose","tag-thromboseprophylaxe","tag-venenthrombose"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1877"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1877\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}